REPCF CA76027P4006

Delayed OTC Markets - 05/13 10:18:29 am EDT
0.0952	USD		-4.80%

03/29	REPLICEL LIFE SCIENCES : 51-102F3 MATERIAL CHANGE REPORT - Form 6-K	PU
03/29	REPLICEL LIFE SCIENCES : New DermaPrecise™ patent application and patents granted for tendinopathy and skin rejuvenation technologies in key markets - Form 6-K	PU
03/22	RepliCel Announces Non-brokered Private Placement	AQ

News

Most relevant

Official Publications

Sector news

Most relevant news about REPLICEL LIFE SCIENCES INC.

03/29	REPLICEL LIFE SCIENCES : 51-102F3 MATERIAL CHANGE REPORT - Form 6-K	PU
03/29	REPLICEL LIFE SCIENCES : New DermaPrecise™ patent application and patents granted fo..	PU
03/22	RepliCel Announces Non-brokered Private Placement	AQ
03/21	RepliCel Life Sciences Inc. announced that it expects to receive CAD 1.5 million in fun..	CI
2021	REPLICEL LIFE SCIENCES : 51-102F3 MATERIAL CHANGE REPORT - Form 6-K	PU
2021	REPLICEL LIFE SCIENCES : Closed Final Tranche of Strategic Investment Commitment	PU
2021	RepliCel Life Sciences Inc. Terminates License Agreement with Shiseido	CI
2021	RepliCel Life Sciences Inc. announced that it has received CAD 0.99892 million in fundi..	CI
2021	RepliCel Life Sciences Inc. announced that it expects to receive CAD 0.99892 million in..	CI
2021	RepliCel Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Mon..	CI
2021	REPLICEL LIFE SCIENCES : NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS - Fo..	PU
2021	REPLICEL LIFE SCIENCES : Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study ..	PU
2021	RepliCel Life Sciences Inc.’S Clinical Advisory Team Delivers Skin Rejuvenation Cl..	CI
2021	RepliCel Ships DermaPreciseTM Injector Prototypes and Consumables to Independent Labora..	PU
2021	RepliCel's Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to..	PU
2021	Testing progresses to next-phase; results lead to some component upgrades to ensure opt..	PU
2021	RepliCel Announces DermaPrecise Trademark for Dermal Injector Product Line	PU
2021	Replicel Announces Dermaprecise Trademark for Dermal Injector Product Line	CI
2021	RepliCel Announces Dermal Injector Update	PU
2021	RepliCel Life Sciences Inc. Announces Dermal Injector Update	CI
2021	REPLICEL LIFE SCIENCES : Files Notice of Arbitration against Shiseido Company to Resolve i..	PU
2021	REPLICEL LIFE SCIENCES : Files Notice of Arbitration against Shiseido Company to Resolve i..	PU
2021	REPLICEL LIFE SCIENCES : 51-102F3 MATERIAL CHANGE REPORT - Form 6-K	PU
2021	REPLICEL LIFE SCIENCES : Appoints One of Japan's Foremost Regenerative Medicine Industry B..	AQ
2021	REPLICEL LIFE SCIENCES : Kunihiko Suzuki, one of the leading pioneers in Japan's emerging ..	PU
2021	REPLICEL LIFE SCIENCES : News Release dated September 16, 2021 - Form 6-K	PU
2021	REPLICEL LIFE SCIENCES : Appoints One of Japan's Foremost Regenerative Medicine Industry B..	PU
2021	RepliCel Life Sciences Inc. Appoints Kunihiko Suzuki as Senior Strategic Advisor to Its..	CI
2021	REPLICEL LIFE SCIENCES : and University of Victoria Collaboration Leads to Bioengineering ..	PU
2021	RepliCel Life Sciences Inc. and University of Victoria Collaboration Leads to Bioengine..	CI
2021	Replicel Life Sciences Inc. Reports Earnings Results for the Second Quarter Ended June ..	CI
2021	REPLICEL LIFE SCIENCES : Announces Closing of Debt Settlement (Form 6-K)	PU
2021	REPLICEL LIFE SCIENCES : Clinical development of RepliCel's skin rejuvenation and tendon r..	PU
2021	RepliCel Applies for Manufacturing Approval for its Collagen and Tissue Regeneration Ce..	CI
2021	REPLICEL LIFE SCIENCES : Professor Tsukasa Kumai, member of the Japan's Olympic Committee ..	PU
2021	REPLICEL LIFE SCIENCES : Targets for 2021 include dermal injector commercial launch, new p..	PU
2021	REPLICEL LIFE SCIENCES : Announces Debt Settlement (Form 6-K)	PU
2021	REPLICEL LIFE SCIENCES : Applies for Manufacturing Approval for Its Collagen and Tissue Re..	AQ
2021	RepliCel Life Sciences Inc. Applies for Manufacturing Approval for its Collagen and Tis..	CI
2021	REPLICEL LIFE SCIENCES : Adds Independent Director	PU
2021	RepliCel Life Sciences Inc. Appoints Gary Boddington to the Board of Directors	CI
2021	RepliCel Life Sciences Inc. announced that it has received $0.16152 million in funding	CI
2021	REPLICEL LIFE SCIENCES : Announces Closing of Debt Settlement	AQ
2021	RepliCel Life Sciences Inc. announced that it has received $0.111574 million in funding	CI
2021	RepliCel Life Sciences Inc. announced that it expects to receive $0.111574 million in f..	CI
2021	RepliCel Life Sciences Inc. Reports Earnings Results for the First quarter Ended March ..	CI
2021	Replicel Life Sciences Inc. Receiveds the First Units of Its Dermal Injector and Is Nea..	CI
2021	REPLICEL LIFE SCIENCES : Launches Testing of Dermal Injector Units	PU
2021	REPLICEL LIFE SCIENCES : Launches Preparations for Second Skin Rejuvenation and Tendon Reg..	PU
2021	RepliCel Announces Appointment of Akimichi Moritaas as Clinical Advisor	CI
2021	Replicel Launches the Next Stage of A Research Project with The University of British C..	CI
2021	REPLICEL LIFE SCIENCES : Launches the Next Stage of a Research Project with the University..	PU
2021	Replicel Life Sciences Inc. Announces Record Year in Patents Granted	CI
2021	REPLICEL LIFE SCIENCES : Announces Record Year in Patents Granted	PU
2021	RepliCel Life Sciences Inc. Appoints Tsukasa Kumai as Clinical Advisor for the Developm..	CI
2021	REPLICEL LIFE SCIENCES : Announces Appointment of Leading Sports Medicine Expert as Orthop..	PU
2021	Replicel Life Sciences Inc. Reports Earnings Results for the Full Year Ended December 3..	CI
2021	REPLICEL LIFE SCIENCES : Closes Second Tranche of Strategic Investment Commitment	PU
2021	RepliCel Life Sciences Inc. announced that it has received CAD 0.492091 million in fund..	CI
2021	REPLICEL BRIEF : Up 6.6% As Presents Its Technology Development and Commercialization Plan..	MT
2021	REPLICEL BRIEF : Down More Than 8% As Closes First Tranche of Strategic Investment Commitm..	MT
2021	REPLICEL BRIEF : CEO Says Targets for 2021 Include "Dermal Injector Commercial Launch, New..	MT
2021	REPLICEL BRIEF : CEO Provides Corporate Update; Comes After Stock Jumped 26.5% on Friday	MT
2021	RepliCel Life Sciences Inc. announced that it expects to receive CAD 0.492091 million i..	CI
2020	RepliCel Life Sciences Inc. Announces Restatement of Earnings Results for the Year Ende..	CI
2020	Replicel Life Sciences Inc. Announces Resignation of Directors	CI
2020	Replicel Life Sciences Inc. Reports Earnings Results for the Third Quarter Ended Septem..	CI
2020	RepliCel Life Sciences Inc. Announces Distribution Partnership with Mainpointe Pharmace..	CI
2020	REPLICEL LIFE SCIENCES : Up 17.5% As Details Binding Term Sheet for Strategic Investment, ..	MT
2020	REPLICEL BRIEF : Up 17.5% As Details Binding Term Sheet For Strategic Investment and U.S. ..	MT
2020	REPLICEL LIFE SCIENCES : Announces a Binding Term Sheet For Strategic Investment and U.S. ..	AQ
2020	RepliCel Announces a Binding Term Sheet For Strategic Investment and U.S. Partnership	GL
2020	RepliCel Life Sciences Inc. announced that it expects to receive CAD 2.7 million in fun..	CI
2020	REPLICEL LIFE SCIENCES : Q3 2020 Management Update	AQ
2020	RepliCel Life Sciences Inc. Postpones Filing of Interim Financial Statements and MD&A D..	CI

1 2 3 Next

Upcoming event on REPLICEL LIFE SCIENCES INC.

06/01/22

Q1 2022 Earnings Release (Projected)

Company calendar

Upcoming sector events

07/27/22	VERTEX PHARMACEUTICALS INCORPORATED : Interim 2022 Earnings Release (Projected)
07/27/22	GILEAD SCIENCES, INC. : Interim 2022 Earnings Release (Projected)
08/04/22	REGENERON PHARMACEUTICALS, INC. : Interim 2022 Earnings Release (Projected)
08/08/22	BIONTECH SE : Interim 2022 Earnings Release

More events

Sector

Healthcare
	Pharmaceuticals & Medical Research
		Biotechnology & Medical Research
			Biotechnology & Medical Research
				Bio Therapeutic Drugs